Encourage the first generic drug idea: The top five pharmaceutical companies can enjoy preferential pricing

The brewing policy that has long encouraged the first generic drug is nearing maturity. According to the third session of the Forum on Generic Pharmaceutical Industry and Technology Development, the Development and Reform Commission and the Food and Drug Administration and other departments have recently formed a regulation and adjustment approach that combines pricing and approval systems. In addition to the five first generic drug companies that enjoy preferential pricing, No other homogenized patent imitation approvals will be opened in time.

Wang Bo, deputy head of the China Pharmaceutical Enterprise Management Association, said that the current batch of chemical drugs has exceeded 120,000, and most of them are generic drugs. According to industry insiders, generic drugs account for more than 97% of the domestic chemical drug market, and generic drugs have experienced overheating.

In response to this, the new version of the “Drug Price Management Approach (Draft for Soliciting Opinions)” publicly solicited opinions from the National Development and Reform Commission (NDRC). It proposes to regulate the overheating of generic drugs through a combination of pricing and examination and approval systems. The specific measures include: the first three after the end of the patent drug protection period in China. For generic drugs that are listed on the market, the first generic drug can be priced separately within 30% of the unitary pricing, while the price of the second generic and the third generic drug can be 90% and 81% of the price of the first generic drug.

According to the above opinion, the first three generic drugs can enjoy preferential pricing. However, since the drug approval is mainly in the drug regulatory department, and the related work involves multi-sectoral coordination and various factors, the above method has not yet been formally introduced until now.

The current thinking has been basically mature. In the future, or to be two batches of generic drugs and three generic drugs, plus one first generic drug company, it means that there will be five generic drugs that can enjoy differentiated or individual pricing treatment in the future.